Changes for page Pieris Pharmaceuticals

Last modified by Asif Farooqui on 2019/12/09 16:57
From version < 1.4 >
edited by Asif Farooqui
on 2019/12/09 16:57
To version < 2.1 >
edited by Asif Farooqui
on 2019/12/09 16:57
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -4,7 +4,7 @@
4 4  
5 5  = =
6 6  
7 -Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.{{footnote}}https://fintel.io/doc/sec-pirs-pieris-pharmaceuticals-10k-2018-march-15-17944{{/footnote}}
7 +Pieris Pharmaceuticals (PIRS) is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.{{footnote}}https://fintel.io/doc/sec-pirs-pieris-pharmaceuticals-10k-2018-march-15-17944{{/footnote}}
8 8  
9 9  Each of its development programs focus on the following:
10 10  
This site is funded and maintained by Fintel.io